The Division Renal Disease and Hypertension of Medical Faculty Associates is a leader in Renal research in the Washington, DC area. We are currently conducting clinical trials enrolling patients who have iron deficiency anemia. There are a few studies that are in development or the Institutional Review Board (IRB) approval process. In most cases, participant labs and study medications are provided free of charge. Principal Investigators include Dr. Dominic S.C. Raj, Dr. Manuel T. Velasquez, Dr. Kevin Sterling and Dr. Susie Q. Lew. Please contact the Division of Renal Diseases and Hypertension at (202) 741-2284 for more information.

Iron Deficiency Anemia

**1VIT09030: Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal function**

**Description:** This study is being done to see how safe an investigational new drug Ferric Carboxymaltose (FCM) is and how well it will work to treat people with iron deficiency anemia and impaired renal (kidney) function. The purpose of this study is to determine if FCM is as safe and effective as Venofer®, which is currently available to treat anemia in patients with impaired renal function. For more information, contact Roshni S. Bastian, MPH at (202) 741-2284.

**TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE**

- **SAVOR-TIMI 53: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes**

**Description:** Saxagliptin (sold as Onglyza®) is a drug taken as a pill that is approved by the U.S. Food and Drug Administration (FDA) for lowering glucose (sugar) levels in people with type 2 diabetes mellitus. The purpose of this study is to see if adding saxagliptin to the other medications you are currently taking for diabetes can reduce the risk of cardiovascular disease, complications from diabetes. For more information, contact Roshni S. Bastian, MPH at (202) 741-2284 or visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (Reference # NCT01107886).

**Bacteremia and Complicated Skin Infection**

**DAP-RENSE-0805: A Prospective, Multicenter, Randomized, Evaluator-Blinded, Comparator-Controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia among Subjects with Moderate or Severe Renal Impairment**

**Description:** This is a research study designed to look at the safety and efficacy of daptomycin
in subjects with complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria or bacteremia (blood stream infections) caused by *Staphylococcus aureus* (*S. aureus*) and either moderate renal (kidney) impairment or severe renal impairment. Daptomycin (Cubicin®) is an antibiotic approved by the Food and Drug Administration (FDA) for the treatment of complicated skin and skin structure infections at a dose of 4 mg/kg once daily and *S. aureus* bacteremia including right-sided infective endocarditis at a dose of 6 mg/kg once daily in people with normal kidney function. If you take part in this study, you will be assigned to receive treatment with either daptomycin or with a different medication which is commonly used to treat this type of infection (conventional antibiotic). The conventional antibiotics that will be used in this trial are vancomycin, nafcillin, or oxacillin/cloxacin, and all are approved by the FDA. For more information contact **Roshni S. Bastian, MPH** at (202) 741-2284 or visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (Reference # NCT01104662).